Evommune (EVMN) Return on Equity [ROE] (2025 - 2026)
Evommune (EVMN) posted Return on Equity [ROE] of -32.52% for Q2 2026, up 0.81 percentage points from the prior quarter.
Powered by 
Analysis
Evommune (EVMN) Return on Equity [ROE] (2025 - 2026) Analysis & Trends
For FY2025, Evommune's Return on Equity [ROE] came in at -253.54%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,171.06 Bn | 1,139.65 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 634.89 Bn | 553.42 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 503.32 Bn | 476.44 Bn | 12.70 Bn | - |
| 4 | Merck | 377.44 Bn | 331.82 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 303.91 Bn | 267.90 Bn | 11.24 Bn | 31.52% |
| 6 | Astrazeneca | 267.03 Bn | 240.72 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 241.88 Bn | 197.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 194.01 Bn | 168.20 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 172.57 Bn | 119.21 Bn | 10.94 Bn | 4.97% |
| 10 | Evommune | 188.99 Mn | -448.53 Mn | - | -32.52% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.52% |
| Mar 31, 2026 | -33.33% |
| Dec 31, 2025 | -693.29% |
API Access
Evommune Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=EVMN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "EVMN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=EVMN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();